Skip to main content
Clinical Trials/NCT02639793
NCT02639793
Unknown
Phase 4

A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor

Heikki Huikuri2 sites in 1 country300 target enrollmentJanuary 2016

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Heikki Huikuri
Enrollment
300
Locations
2
Primary Endpoint
Free of atrial fibrillation
Last Updated
10 years ago

Overview

Brief Summary

The study will assess the atrial fibrillation burden recorded By implantable loop recorder at 12 and 24 months compared to baseline. The patients with clinical indication fo catheter ablation of paroxysmal atrial fibrillation will be randomized to three techniques: manual radiofrequency ablation, radiofrequency ablation using remote magnet monitoring, and cryoablation.

Detailed Description

A total of 300 patients will be randomized to three different catheter ablation techniques (100 patients/group); radiofrequency ablation using remote magnet navigation, radiofrequency ablation using manual method, and cryoablation. A loop recorder (REVEAL) is implanted one month before the catheter ablation of paroxysmal atrial fibrillation and the effects of atrial fibrillation burden will be compared between the three methods at 12 and 24 months after ablation excluding the first three months´ blanking period. The primary endpoints are: 1. the proportion of patients remaining free from atrial fibrillation, atrial flutter or atrial tachycardia (\> 2 minutes) recorded by the implantable cardiac monitor (Medtronic) at 24 months follow-up and 2. total atrial fibrillation burden recorded by the loop recorder. Other endpoints: 1. Atrial fibrillation burden in 7 days Holter recording at 12 and 24 months compared to baseline, 2. the time to first documented symptomatic and asymptomatic recurrence of atrial fibrillation 3. prescription of antiarrhythmic drugs after the 3 months blanking period following the ablation 4. re-ablation after the index ablation procedure, 5. total procedural duration; 6. total time of fluoroscopy and radiation dose; 7. number and duration of cardiovascular hospitalization; 8. quality of life questionnaires at 12 months and 24 month compared with baseline, 9. cognitive function at 12 and 24 month compared with baseline, 10. cost-efficacy of the different ablation techniques.

Registry
clinicaltrials.gov
Start Date
January 2016
End Date
January 2020
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Heikki Huikuri
Responsible Party
Sponsor Investigator
Principal Investigator

Heikki Huikuri

Professor

University of Oulu

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Any contraindication to catheter ablation

Outcomes

Primary Outcomes

Free of atrial fibrillation

Time Frame: 24 months

the proportion of patients remaining free from AF, atrial flutter (AFL) or atrial tachycardia (AT) (\> 2 minutes) recorded by the implantable cardiac monitor (ICM, Reveal, Medtronic Co.) at 24 months.

Secondary Outcomes

  • Total AF burden(24 months)
  • Incidence of adverse events(24 months)

Study Sites (2)

Loading locations...

Similar Trials